| Sandra Tambi Jarbah, AA | |
|
750 E Adams St, Syracuse, NY 13210-2306 | |
| (315) 464-6635 | |
| Not Available |
| Full Name | Sandra Tambi Jarbah |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 750 E Adams St, Syracuse, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184011173 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 261 (Florida) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sandra Tambi Jarbah, AA 750 E Adams St, Syracuse, NY 13210-2306 Ph: (315) 464-6635 | Sandra Tambi Jarbah, AA 750 E Adams St, Syracuse, NY 13210-2306 Ph: (315) 464-6635 |
News Archive
Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."
A study published in the current issue of the Journal of the National Cancer Institute (JNCI) concludes that genotyping of specific high-risk types of the human papillomavirus (HPV), the cause of virtually all cases of cervical cancer, can benefit clinical practice by enabling more focused attention on women who are at highest risk, announced Digene Corporation.
Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin Lymphoma.
Researchers report a skyrocketing increase in the number of visits to the emergency department for kids with sports-related traumatic brain injuries, such as concussions.
Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.
› Verified 9 days ago